Trial · NCT01929616
Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
NCT01929616, Phase 2, Completed, Jules Bordet Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C). Trials, record NCT01929616. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01929616
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
- NCT number
- NCT01929616
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 141 participants, actual
- Lead sponsor
- Jules Bordet Institute
- Conditions
- Advanced Chemorefractory Colorectal Adenocarcinoma
- Interventions
- regorafenib
- First posted
- 2013-08-28
- Last updated
- 2019-06-25
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | 2 years from first patient in | |
| Secondary | Occurence of Adverse events | Every 28 days till 28 days after stopping therapy. An average of 2 months is expected. | Assessment of safety will follow the WHO guidelines and classified according to NCI-CTCAE v. 4.0 and will be performed every 28 days until 28 days (safety follow up visit) after stopping therapy. Reasons for stopping therapy may include progression of disease or unbearable toxicities, or patient's decision. |
| Secondary | Evaluation of tumour response | Every 2 months till progression of the disease. An average of 2 months is expected. | RECIST 1.1-based radiological assessment (CT or MRI) will be made every 2 cycles, starting at day 28 of the second cycle till demonstration of progressive disease. An average of 2 months is expected. |
| Secondary | Metabolic response assessed by FDG PET | 2 FDGPET will be perfomed : at Baseline (day 0) and at D14 | FDGPET will be done twice during the study course : at baseline (at day 0, before treatment begin) and after 2 weeks. |
| Secondary | Molecular aberrations | at day 0 (before treatment begins) and at D14, then repeated every 2 months until progression. An average of 2 months is expected. | Genetic, epigenetic and molecular aberrations will be investigated using gene expression profiling, RNA and exome sequencing, and methylation profiling on the tumor biopsies and repeated blood samples collected during the trial. The relationship between the molecular aberrations,the patient's outcome (PFS, OS) and with metabolic response after treatment with regorafenib will be studied. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01929616
GET https://conductscience.org/api/trials/v1/NCT01929616/registered